Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AADI NASDAQ:PRAN NASDAQ:PYRGF NASDAQ:WHWK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$1.85-5.1%$1.87$1.21▼$3.81$45.69M0.68257,690 shs289,056 shsPRANAlterity Therapeutics$4.61-0.6%$1.41$1.09▼$2.91$41.03M1.05130,956 shs36,628 shsPYRGFPyroGenesis Canada$0.32-1.5%$0.34$0.30▼$0.71$59.88M0.8411,493 shs36,346 shsWHWKWhitehawk Therapeutics$1.86+0.5%$0.00$1.21▼$3.81$87.58M0.55162,207 shs7,302 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience+0.52%-2.99%-4.41%+24.20%+24.20%PRANAlterity Therapeutics+3.92%+18.67%+5.10%+32.57%+131.11%PYRGFPyroGenesis Canada-1.51%-5.27%-7.65%+0.22%-51.63%WHWKWhitehawk Therapeutics-5.13%-6.09%+184,999,900.00%+184,999,900.00%+184,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAADIAadi Bioscience0.3857 of 5 stars1.00.00.00.00.02.51.3PRANAlterity TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APYRGFPyroGenesis Canada0.0914 of 5 stars0.02.00.00.00.01.70.0WHWKWhitehawk TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAADIAadi Bioscience 2.00Hold$1.67-9.91% DownsidePRANAlterity Therapeutics 0.00N/AN/AN/APYRGFPyroGenesis Canada 0.00N/AN/AN/AWHWKWhitehawk Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAADIAadi Bioscience$25.07M1.82N/AN/A$4.29 per share0.43PRANAlterity Therapeutics$150K273.53N/AN/A$1.40 per share3.29PYRGFPyroGenesis Canada$9.14M6.55N/AN/A($0.01) per share-31.97WHWKWhitehawk Therapeutics$25.98M3.37N/AN/A$2.12 per share0.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAADIAadi Bioscience-$65.76M-$2.35N/AN/AN/A-246.06%-71.87%-57.28%8/5/2025 (Estimated)PRANAlterity Therapeutics-$6.40M-$0.70N/A∞N/AN/AN/AN/AN/APYRGFPyroGenesis Canada-$21.12M-$0.02N/A∞N/A-115.14%N/A-60.81%N/AWHWKWhitehawk Therapeutics-$63.69M$0.1611.62∞N/A99.42%-56.73%-48.68%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAADIAadi BioscienceN/AN/AN/AN/AN/APRANAlterity TherapeuticsN/AN/AN/AN/AN/APYRGFPyroGenesis CanadaN/AN/AN/AN/AN/AWHWKWhitehawk TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAADIAadi BioscienceN/A4.894.54PRANAlterity TherapeuticsN/A4.37N/APYRGFPyroGenesis CanadaN/A0.600.50WHWKWhitehawk TherapeuticsN/A18.9518.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAADIAadi Bioscience52.08%PRANAlterity Therapeutics3.63%PYRGFPyroGenesis Canada0.03%WHWKWhitehawk Therapeutics52.08%Insider OwnershipCompanyInsider OwnershipAADIAadi Bioscience37.30%PRANAlterity Therapeutics38.80%PYRGFPyroGenesis Canada47.68%WHWKWhitehawk Therapeutics49.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAADIAadi Bioscience4024.70 million15.49 millionOptionablePRANAlterity Therapeutics148.90 millionN/ANot OptionablePYRGFPyroGenesis Canada90187.31 million96.34 millionNo DataWHWKWhitehawk Therapeutics4047.11 million23.60 millionN/APRAN, WHWK, PYRGF, and AADI HeadlinesRecent News About These CompaniesNo headlines for this company have been tracked by MarketBeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRAN, WHWK, PYRGF, and AADI Company DescriptionsAadi Bioscience NASDAQ:AADI$1.85 -0.10 (-5.13%) As of 07/17/2025Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.Alterity Therapeutics NASDAQ:PRANAlterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.PyroGenesis Canada NASDAQ:PYRGF$0.32 0.00 (-1.51%) As of 07/17/2025 03:19 PM EasternPyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.Whitehawk Therapeutics NASDAQ:WHWK$1.86 +0.01 (+0.49%) As of 10:04 AM EasternAadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate How Goldman Sachs Earnings Help You Strategize Your Portfolio Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
